Orsini Specialty Pharmacy Announces Access To Tiopronin For The Treatment Of Severe Homozygous Cystinuria
ELK GROVE VILLAGE, Ill., July 22, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA® (tiopronin). Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients nine years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. For more information about tiopronin, please see the Full Prescribing Information.
- ELK GROVE VILLAGE, Ill., July 22, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA (tiopronin).
- Cystinuria is a rare, inherited disease characterized by the build-up of the amino acid cystine, a building block of most proteins, in the kidneys and bladder.
- "High touch care coordination and collaboration drive our unique pharmacy care model, and we are honored to help provide access to tiopronin to patients with severe homozygous cystinuria."
- Providing patients with comprehensive and compassionate care since 1987,Orsini is the leading, independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions.